Clinical Utility of the Novel Oncological Criteria of Resectability for Advanced Hepatocellular Carcinoma.

ABSTRACT:

Introduction

Introduction of new systemic therapies for hepatocellular carcinoma (HCC) has led to the development of new oncological criteria of resectability for the resectability of HCC. This study was aimed at validating the prognosticating ability and clinical utility of the resectability classification based on the novel criteria in real-world clinical practice.

Methods

This study was conducted in 1,822 patients who had undergone curative resection for HCC (population 1) and 107 patients with unresectable disease who had received lenvatinib therapy (population 2). Patients were classified into three groups according to the novel oncological criteria for resectability (R, resectable; BR1, borderline resectable 1; and BR2, borderline resectable 2), and the prognosticating

SUBMITTER: Shindoh J 

PROVIDER: S-EPMC11649256 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature